Diabetes Drug Side-Effects Lead to FDA Warning

Popular Type 2 Diabetes Drug Side-Effects Leads to FDA Warning

NATIONAL—INVOKANA is a popular Diabetes medication known as Canagliflozin. Invokana is a gliflozin class drug and is also a subtype 2 sodium-glucose transport inhibitor. This means it is used for treatment, but Invokana is specifically for Type 2 Diabetes. However, use of this drug could increase risk of Ketoacidosis, Kidney Failure, Heart Attack or Stroke, FDA warns.

The FDA will commonly issue a warning when serious side-effects are noted and reported. But their warning does not mean they pull the drug from circulation. Here is a list of brand name drugs that are currently under investigation by the FDA:

  • INVOKANA (Invokamet)

Invokana was finally pulled from circulation in 2017 due to the major complications. However, the FDA placed a new label on the drug listing the major side effects. Consequently, sales have shrunk dramatically, leading to increased sales for Jardiance and Farxiga.

Suffered the harmful side effects as a result of using INVOKANA? You could be entitled to monetary compensation. Then you have the right to hold the manufacturer of that drug responsible for your injuries. Call TRIPP LAW FIRM – Personal Injury Law at (727)398-2900 in Pinellas/Pasco, (352)610-1080 in Hernando/Citrus, and (941)479-0201 in Manatee/Sarasota, for an immediate, confidential case evaluation. Therefore, there is NO Fee and NO Costs if we do not obtain a Recovery for YOU!

At the TRIPP LAW FIRM, we have the necessary experience to protect you and your family’s legal rights and pursue the appropriate damages. Thus, don’t hesitate to call us. We answer our phones 24/7/365. The injury law team and staff private investigators at the TRIPP LAW FIRM are ready on a moment’s notice.

TRIPP LAW FIRM – Personal Injury Law – Available 24/7

TOLL FREE: (888) 392-LAWS (5297)



SAFETY ANNOUNCEMENT: FDA Drug Safety Communication: FDA strengthens kidney warnings for diabetes medicines canagliflozin (Invokana, Invokamet) and dapagliflozin (Farxiga, Xigduo XR), U.S. Food & Drug Administration (Jun. 14, 2016), available at http://www.fda.gov/Drugs/DrugSafety/ucm505860.htm.

Relevant Practice Areas

Medical Malpractice Attorney

Leave a Reply

Your email address will not be published. Required fields are marked *